Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer

References

• Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154–173. doi:10.1016/j.ccell.2020.10.001
   PubMed Web of Science ®Google Scholar
• Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017;28(suppl_8):viii1–viii7. doi:10.1093/annonc/mdx444
   PubMedGoogle Scholar
• Xin YJ, Hodge JP, Oliva C, Neftelinov ST, Hubbard-Lucey VM, Tang J. Trends in clinical development for PD-1/PD-L1 inhibitors. Nat Rev Drug Discov. 2020;19(3):163–164. doi:10.1038/d41573-019-00182-w
   PubMed Web of Science ®Google Scholar
• Yang S, Wei W, Zhao Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci. 2020;16(11):1767–1773. doi:10.7150/ijbs.41105
   PubMed Web of Science ®Google Scholar
• Liu J, Yang S, Cao B, et al. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol. 2021;14(1):21. doi:10.1186/s13045-020-01024-8
   PubMed Web of Science ®Google Scholar
• Liu S, Liang J, Liu Z, et al. The role of CD276 in cancers. Front Oncol. 2021;11:654684. doi:10.3389/fonc.2021.654684
   PubMedGoogle Scholar
• Zhou W-T, Jin W-L. B7-H3/CD276, an emerging cancer immunotherapy. Front Immunol. 2021;12:701006. doi:10.3389/fimmu.2021.701006
   PubMed Web of Science ®Google Scholar
• Lee Y-H, Martin-Orozco N, Zheng P, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017;27(8):1034–1045. doi:10.1038/cr.2017.90
   PubMed Web of Science ®Google Scholar
• Suh W-K, Gajewska BU, Okada H, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol. 2003;4(9):899–906. doi:10.1038/ni967
   PubMed Web of Science ®Google Scholar
• Prasad DVR, Nguyen T, Li Z, et al. Murine B7-H3 is a negative regulator of T cells. J Immunol. 2004;173(4):2500–2506. doi:10.4049/jimmunol.173.4.2500
   PubMed Web of Science ®Google Scholar
• Wang C, Li Y, Jia L, et al. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. Cell Stem Cell. 2021;28(9):1597–1613.e7. doi:10.1016/j.stem.2021.04.011
   PubMed Web of Science ®Google Scholar
• Hagelstein I, Engel M, Hinterleitner C, et al. B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma. Front Immunol. 2022;13:1002898. doi:10.3389/fimmu.2022.1002898
   PubMed Web of Science ®Google Scholar
• Du H, Hirabayashi K, Ahn S, et al. Antitumor responses in the absence of toxicity in solid tumors by targeting B7-H3 via chimeric antigen receptor t cells. Cancer Cell. 2019;35(2):221–237.e8. doi:10.1016/j.ccell.2019.01.002
   PubMed Web of Science ®Google Scholar
• Vitanza NA, Wilson AL, Huang W, et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma, preliminary first-in-human bioactivity and safety. Cancer Discov. 2022. doi:10.1158/2159-8290.CD-22-0750
   Web of Science ®Google Scholar
• Chapoval AI, Ni J, Lau JS, et al. B7-H3, a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol. 2001;2(3):269–274. doi:10.1038/85339
   PubMed Web of Science ®Google Scholar
• Lupu CM, Eisenbach C, Kuefner MA, et al. An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo. J Gastrointest Surg. 2006;10(5):635–645. doi:10.1007/BF03239969
   PubMed Web of Science ®Google Scholar
• Loos M, Hedderich DM, Ottenhausen M, et al. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer. 2009;9:463. doi:10.1186/1471-2407-9-463
   PubMed Web of Science ®Google Scholar
• Picarda E, Galbo PM, Zong H, et al. The immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity development. Sci Adv. 2022;8(17):eabm7012. doi:10.1126/sciadv.abm7012
   PubMed Web of Science ®Google Scholar
• Bolouri H, Farrar JE, Triche T, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24(1):103–112. doi:10.1038/nm.4439
   PubMed Web of Science ®Google Scholar
• Notter T, Panzanelli P, Pfister S, Mircsof D, Fritschy J-M. A protocol for concurrent high-quality immunohistochemical and biochemical analyses in adult mouse central nervous system. Eur J Neurosci. 2014;39(2):165–175. doi:10.1111/ejn.12447
   PubMed Web of Science ®Google Scholar
• Detre S, Saclani Jotti G, Dowsett M. A “quickscore” method for immunohistochemical semiquantitation, validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48(9):876–878. doi:10.1136/jcp.48.9.876
   PubMed Web of Science ®Google Scholar
• Liu J, Lichtenberg T, Hoadley KA, et al. An integrated TCGA Pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 2018;173(2). doi:10.1016/j.cell.2018.02.052
   Web of Science ®Google Scholar
• Ru B, Wong CN, Tong Y, et al. TISIDB, an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019;35(20):4200–4202. doi:10.1093/bioinformatics/btz210
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER, A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Hong F, Meng Q, Zhang W, et al. Single-Cell analysis of the pan-cancer immune microenvironment and scTIME portal. Cancer Immunol Res. 2021;9(8):939–951. doi:10.1158/2326-6066.CIR-20-1026
   PubMed Web of Science ®Google Scholar
• Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017. doi:10.1200/PO.17.00073
   PubMed Web of Science ®Google Scholar
• Reinhold WC, Sunshine M, Liu H, et al. CellMiner, a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 2012;72(14):3499–3511. doi:10.1158/0008-5472.CAN-12-1370
   PubMed Web of Science ®Google Scholar
• Shankavaram UT, Varma S, Kane D, et al. CellMiner, a relational database and query tool for the NCI-60 cancer cell lines. BMC Genom. 2009;10:277. doi:10.1186/1471-2164-10-277
   PubMed Web of Science ®Google Scholar
• Ritota M, Comitato R, Manzi P. Cow and ewe cheeses made with saffron, characterization of bioactive compounds and their antiproliferative effect in cervical adenocarcinoma (HeLa) and breast cancer (MDA-MB-231) cells. Molecules. 2022;27(6):1995. doi:10.3390/molecules27061995
   PubMed Web of Science ®Google Scholar
• Li X-Q, Bai Y-L, Zhang D-L, Jiao H-S, He R-X. Euphornin reduces proliferation of human cervical adenocarcinoma HeLa cells through induction of apoptosis and G2/M cell cycle arrest. Onco Targets Ther. 2018;11:4395–4405. doi:10.2147/OTT.S166018
   PubMed Web of Science ®Google Scholar
• Guan Y, Luan Y, Xie Y, et al. Chloride channel-3 is required for efficient tumour cell migration and invasion in human cervical squamous cell carcinoma. Gynecol Oncol. 2019;153(3):661–669. doi:10.1016/j.ygyno.2019.03.006
   PubMed Web of Science ®Google Scholar
• Fan L, Liu Z, Zhang Y, et al. MiRNA373 induces cervical squamous cell carcinoma SiHa cell apoptosis. Cancer Biomark. 2018;21(2):455–460. doi:10.3233/CBM-170692
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Gong Z, Zhang J, Guo W. Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer. Cancer Med. 2020;9(23):9052–9063. doi:10.1002/cam4.3505
   PubMed Web of Science ®Google Scholar
• Thorsson V, Gibbs DL, Brown SD, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812–830.e14. doi:10.1016/j.immuni.2018.03.023
   PubMed Web of Science ®Google Scholar
• Jiang M, Jia K, Wang L, et al. Alterations of DNA damage response pathway, Biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharm Sin B. 2021;11(10):2983–2994. doi:10.1016/j.apsb.2021.01.003
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker, utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56. doi:10.1093/annonc/mdy495
   PubMed Web of Science ®Google Scholar
• Dudley JC, Lin M-T, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22(4):813–820. doi:10.1158/1078-0432.CCR-15-1678
   PubMed Web of Science ®Google Scholar
• Picarda E, Ohaegbulam KC, Zang X. Molecular pathways, targeting B7-H3 (CD276) for human cancer immunotherapy. Clin Cancer Res. 2016;22(14):3425–3431. doi:10.1158/1078-0432.CCR-15-2428
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang J, Han S, et al. B7-H3 promotes the proliferation, migration and invasiveness of cervical cancer cells and is an indicator of poor prognosis. Oncol Rep. 2017;38(2):1043–1050. doi:10.3892/or.2017.5730
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu L, Han S, et al. B7-H3 is related to tumor progression in ovarian cancer. Oncol Rep. 2017;38(4):2426–2434. doi:10.3892/or.2017.5858
   PubMed Web of Science ®Google Scholar
• Chen Y, Zhang S, Wang Q, Zhang X. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J Hematol Oncol. 2017;10(1):36. doi:10.1186/s13045-017-0408-0
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhu X, Tang C, Guan X, Zhang W. Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188593. doi:10.1016/j.bbcan.2021.188593
   PubMed Web of Science ®Google Scholar
• Nguyen PHD, Ma S, Phua CZJ, et al. Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma. Nat Commun. 2021;12(1):227. doi:10.1038/s41467-020-20171-7
   PubMed Web of Science ®Google Scholar
• Chen AX, Gartrell RD, Zhao J, et al. Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor marker. Genome Med. 2021;13(1):88. doi:10.1186/s13073-021-00906-x
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Murakami R, Hamanishi J, et al. B7-H3 suppresses antitumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression. Cancer Immunol Res. 2022;10(1):56–69. doi:10.1158/2326-6066.CIR-21-0407
   PubMed Web of Science ®Google Scholar
• Zhang T, Jiang B, Zou S-T, Liu F, Hua D. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3. World J Gastroenterol. 2015;21(6):1804–1813. doi:10.3748/wjg.v21.i6.1804
   PubMed Web of Science ®Google Scholar
• Liu H, Tekle C, Chen Y-W, et al. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther. 2011;10(6):960–971. doi:10.1158/1535-7163.MCT-11-0072
   PubMed Web of Science ®Google Scholar
• Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926–1936. doi:10.1056/NEJMoa1810527
   PubMed Web of Science ®Google Scholar